EcoR1 Capital secured Board seat in Galapagos (GLPG)

Key Summary: On August 23, 2024, EcoR1 Capital (9.9%) announced plans to discuss company performance, operations, strategic opportunities, and governance, including Board composition, with management and the board. On October 6, 2024, the Board appointed Mr. Nodelman from EcoR1 CAPITAL as a non-executive, non-independent director.

Market Cap: $2 billion | Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. 

EcoR1 Capital

• On August 23, 2024, EcoR1 Capital (9.9%) stated that it intends to communicate with the management and board about a variety of topics relating to the company’s performance, business, operations, strategic opportunities and governance, including Board composition. Source

• On October 6, 2024, the Board appointed Mr. Nodelman from EcoR1 CAPITAL as a non-executive, non-independent director, effective October 7, 2024. They also plan to nominate and recommend him for a four-year term as director at the upcoming shareholders' meeting.

Van Herk Investments

On November 2, 2021, Van Herk Investments (7.1%) provided notice to the company of its intent to nominate Mr. Dharminder Chahal for election to the board. Sourceurce